P/E at 38.05 vs Industry's 36.78: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Reflects Confidence Amid Sector Parity

The current P/E of Sun Pharmaceutical Industries Ltd stands at 38.05, slightly above the Pharmaceuticals & Biotechnology industry average of 36.78. This premium, while not extreme, suggests investors are willing to pay a higher multiple for the company’s earnings relative to peers. The market capitalisation of ₹4,76,387.96 crores classifies it firmly as a large-cap stock, reinforcing its stature within the sector.

This valuation premium may be interpreted as a reflection of the company’s robust fundamentals and market positioning. However, it also raises the question of whether the premium is justified by recent performance metrics — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating? The four-parameter analysis factors in the valuation premium alongside momentum and technical indicators.

Performance Across Timeframes: Consistent Outperformance with Positive Momentum

Examining returns over multiple periods reveals a consistent pattern of outperformance versus the Sensex. Over one year, the stock has gained 16.06%, contrasting with the Sensex’s 4.75% decline. Year-to-date, the stock is up 15.45%, while the Sensex has fallen 9.09%. Even over three months, Sun Pharmaceutical Industries Ltd has posted an 11.61% gain, compared to a marginal Sensex decline of 0.03%.

Shorter-term momentum is also positive, with a 1-month return of 6.03% and a 1-week gain of 2.19%, both comfortably ahead of the Sensex’s respective 0.97% and 0.94%. The stock has recorded three consecutive days of gains, accumulating a 2.63% rise in that period. This steady upward trajectory contrasts with the broader market’s more muted performance, highlighting the stock’s relative strength.

However, the 1-day performance shows a more modest 0.42% increase, slightly underperforming the Sensex’s 0.92% gain on the same day. This divergence invites the question — is this a temporary pause or a sign of short-term consolidation?

Moving Average Configuration: Bullish Technical Setup Across All Key Averages

The technical picture for Sun Pharmaceutical Industries Ltd is notably constructive. The stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a strong upward trend across both short and long-term horizons. This alignment suggests sustained buying interest and a positive momentum backdrop.

Trading close to its 52-week high — just 0.02% shy of the peak price of ₹1,992.5 — further underscores the strength of the current rally. The opening price of ₹1,992.1 on the latest trading day and the absence of significant intraday range movement indicate a stable price environment. The stock’s ability to maintain levels above all major moving averages is a technical endorsement of its resilience.

The 5-day surge partially reverses any earlier weakness — is this a genuine recovery or a relief rally that will fade at the 50 DMA? — the moving average configuration provides the clearest answer.

Sector Context: Pharmaceuticals & Biotechnology Showing Mixed but Stable Results

The Pharmaceuticals & Biotechnology sector has seen four companies declare results recently, with two reporting positive outcomes and two flat, and none negative. This balanced sector performance provides a stable backdrop for Sun Pharmaceutical Industries Ltd to maintain its relative outperformance.

Given the sector’s mixed results, the stock’s consistent gains and premium valuation suggest it is viewed as a leader within its peer group. The sector’s overall stability may be supporting the stock’s upward momentum, but the premium valuation also implies expectations of continued resilience or growth relative to peers.

Rating Context: Previously Rated Hold, Now Reassessed

MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd. The rating was updated on 8 June 2026, reflecting a reassessment of the company’s fundamentals, valuation, and technical outlook. While the current rating is not disclosed, the data-driven approach considers the stock’s premium valuation, strong multi-period performance, and bullish moving average configuration.

Investors may wonder — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider? The current rating provides the answer.

Conclusion: Data Reflects a Stock with Premium Valuation and Strong Momentum

The comprehensive data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap stock trading at a slight premium to its industry peers, supported by consistent outperformance across multiple timeframes. Its technical setup is robust, with the stock trading above all key moving averages and near its 52-week high, signalling sustained investor confidence.

The Pharmaceuticals & Biotechnology sector’s mixed but stable results provide a steady environment for the stock’s momentum to continue. The recent rating reassessment from Hold reflects these evolving fundamentals and technical factors, though the current rating remains undisclosed.

For investors weighing their options, the question remains — what is the current rating for Sun Pharmaceutical Industries Ltd, and how should it influence portfolio decisions?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today